ClinicalTrials.gg
RecruitingNCT07594158Updated Oct 9, 2026

A Study to Evaluate the Safety, Efficacy, and PK of ONO-2017 in Japanese Patients With POS 2 to 17 Year Olds

A Phase 3 interventional study of Cenobamate (tablet) for 12 to < 18 year olds and Cenobamate (syrup) for 2 to < 18 year olds in Partial Epilepsy, sponsored by Ono Pharmaceutical Co., Ltd.. Recruiting at 1 site in Japan. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Ono Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 9, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
2 Years to 17 Years
Sex
All
01

Study summary

Primary objective: To evaluate the safety and tolerability of cenobamate in Japanese pediatric subjects 2-17 years of age with partial-onset (focal) seizures

Read the detailed description

Secondary objectives:

To evaluate the efficacy of cenobamate tablets and suspension in Japanese pediatric subjects with partial onset (focal) seizures

To evaluate the pharmacokinetics of cenobamate tablets and suspension in Japanese pediatric subjects with partial onset seizures

02

Conditions studied

  • Partial Epilepsy

Browse trials for

03

In context

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

This study's planned enrollment of 20 is below the median of 90 across 187 interventional studies indexed under Epilepsies, Partial.

Browse Epilepsies, Partial studies →

Lead sponsor

Ono Pharmaceutical Co., Ltd. is the lead sponsor of 49 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese male or female patients aged 2 to under 18 years at the time of .
  • Patients diagnosed with epilepsy as having POS with uncontrolled seizures at least 6 months prior to informed consent, regardless of the presence or absence of secondarily generalized seizures.
  • Patients who have had POS at least once in 4 weeks before registration. Seizure information can be obtained from the participant's own retrospective patient epilepsy diary, etc.
  • Participants must have been treated with 1 to 3 ASMs at stable doses for at least 2 months before registration.

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of status epilepticus requiring hospitalization within 3 months before registration.
  • Patients with a history of non-epileptic psychogenic seizures.
  • Patients with simple partial seizures without motor symptoms or idiopathic generalized epilepsy.
  • Patients diagnosed with Lennox-Gastaut syndrome.
  • Patients with a history of serious drug-induced reaction (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS, drug-induced hypersensitivity syndrome [DIHS]) or drug-induced rash requiring hospitalization.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    2 to < 18 year olds

    Drug: Cenobamate (tablet) for 12 to < 18 year olds · Drug: Cenobamate (syrup) for 2 to < 18 year olds

Interventions

  • DrugCenobamate (tablet) for 12 to < 18 year olds

    The tablet form of ONO-2017 will be initiated at a dose of 12.5 mg once daily and titrated in the specified method to a target dose of 200 mg per day. The daily dose may be increased/reduced as appropriate according to symptoms within the range not exceeding 400 mg. In addition, depending on clinical response and tolerability, dose titration may be stopped at a dose of ≥ 50 mg per day to establish the maintenance dose. In principle, all doses should be taken with an appropriate amount of water in the morning. The dosage form for the doses will be selected by the principal investigator or designee. ONO-2017 can be treated until ONO-2017 is market approved, enters the market, and becomes available for supply to the study site.

  • DrugCenobamate (syrup) for 2 to < 18 year olds

    The syrup form of ONO-2017 will be administered at a dose equivalent to that for 12-18 year olds on a body weight basis

06

What researchers measure

Primary outcomes

  1. Adverse events and adverse drug reactions

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Japan Red Cross Fukuoka Hospital
    Fukuoka, Japan
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jun 2026 (actual). Primary completion is estimated for Mar 2028, 21 months after the start.

Start moved once since we started tracking on Sep 25, 2026: May 2026 → Jun 2026, on Oct 9, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2026
First posted
May 18, 2026
StartActual
Jun 10, 2026was May 2026
Primary completionEst.
Mar 30, 2028
CompletionEst.
Dec 31, 2029
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
May 30, 2026→Jun 10, 2026 (actual)
Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Start date May 30, 2026→Jun 10, 2026 (now actual)
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07594158
Responsible party
Sponsor
First posted
May 18, 2026
Start date
Jun 10, 2026
Primary completion
Mar 30, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Oct 9, 2026

Study contacts

North America Clinical Trial Support Desk
Contact
clinical_trial@ono-pharma.com
+18665877745 (Toll-Free)
International Clinical Trial Support Desk
Contact
clinical_trial@ono-pharma.com
+17162141777 (Standard)
Project Leader
study director · Ono PharmaceuticalCo., Ltd.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion